Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.
Partners with Pear Therapeutics to launch FDA-approved apps
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene ther...
Spark Therapeutics, Inc.: Spark Therapeutics veranstaltet am Dienstag, 20. Februar, um 8.30 Uhr ET eine Telefonkonferenz, um über die Ergebnisse des Jahres 2017 und über aktuelle geschäftliche Höhepunkte zu sprechen
PHILADELPHIA, 13. Februar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sin...
Repros Therapeutics will release its earnings data before the market opens on Thursday, March 29th. Analysts expect Repros Therapeutics to post earnings of per share for the quarter.
Will work with Pear Therapeutics on a prescription software range
Addex Therapeutics / Addex Therapeutics Equity Research Report Update Issued by valuationLAB . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the cont...
The topic of this month’s newsletter from Drug Discovery Today is Novel Therapeutics.
The topic of this month’s newsletter from Drug Discovery Today is “Therapeutics”
A couple of weeks after the setback of getting a worse-than-expected label from the FDA for Olumiant in rheumatoid arthritis...
Rubius Therapeutics, a biotech that has ambitions to bring “super blood” to the market, has revealed that it has appointed a new CEO to lead the company. Pablo Cagnoni enters the position, joining the biotech from Tizona Therapeutics, which he led as CEO. He joins the company not long after its second successful financing round, after the company raised $100 million in March. read more
PTC Therapeutics Inc. (rare disease and cancer therapeutics) netted $102.5mm through the public offering of 4mm shares at $27...
Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan Legault told INN. The post Antibe Therapeutics Looking for More Licensing Deals appeared first on Investing News Network.
Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. TT701 is a selective androgen receptor modulator that has been shown in a Phase 2 study to significantly increase lean body mass and a measurement of muscle more » The post T...
Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial r...
The various smart phone apps that are being developed to monitor or help manage diseases like diabetes or insomnia are now being referred generally as digital therapeutics (see: Can “Digital Therapeutics” Be as Good as Drugs?). This article provocatively asks the question whether some of these apps can ultimately substitute...
Report estimates a current value of ADXN of CHF 12.5 per share Geneva, Switzerland, 8 January 2018 - Addex Therapeutics (SIX: ADXN) announced today that the independent life science equity researc...
Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies) Initial focus on next generation vector-based therapeutics Boehringer Ingelheim is granted option to in-license sever...
NewsUnder the terms of the agreement, Genentech will utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech.
RNA therapeutics developer Silence Therapeutics announced on Monday that its chief executive Ali Mortazavi will leave the company with immediate effect after a six year stay. Silence said that unti...
Arcturus Therapeutics Announces Expansion of Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI Disorders
SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, announced today that it is extending its partnership with Takeda Pharmaceutical Company Limited (TSE:4502) (Takeda). Under the collaboration, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis...
Shares of G1 Therapeutics Inc. (GTHX) have returned an impressive 103% year-to-date while the iShares NASDAQ Biotechnology Index (ETF)(IBB) is up a paltry 2.8% during the same period.
Sigilon Therapeutics Inc. granted Eli Lilly & Co. exclusive global rights to its Afibromer living therapeutics technology for...
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.
Roche’s subsidiary Genentech has entered into a strategic drug discovery collaboration with Lodo Therapeutics, which is focused on the creation of therapeutics derived from nature that will impact patients across the world.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Rock Ventures. Cedilla is leveraging a growing understanding of the principles that dictate protein stability and appl...